Ethos Technologies
LIFEaTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate …
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2024-2026
All insider trades at Ethos Technologies
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 7/28/2026 | Sell | Gv, 2019 Gp, L.l.c. | Ten Percent Owner | $18.9 | $2,232,761 |
| 7/27/2026 | Sell | Gv, 2019 Gp, L.l.c. | Ten Percent Owner | $19.5 | $3,832,848 |
| 7/24/2026 | Sell | Gv, 2019 Gp, L.l.c. | Ten Percent Owner | $18.9 | $442,001 |
| 7/23/2026 | Sell | Gv, 2019 Gp, L.l.c. | Ten Percent Owner | $19.1 | $1,206,270 |
| 7/22/2026 | Sell | Gv, 2019 Gp, L.l.c. | Ten Percent Owner | $19.2 | $953,467 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)